Home 禄 Business 禄 Manufacturing
Roche eyes firm to boost position
SWISS pharmaceutical company Roche Group yesterday said it is buying California-based medical scanning company BioImagene Inc for US$100 million to strengthen its position in the field of tissue-based cancer diagnostics and research.
"The increasing complexity of new tests and technologies creates tremendous need for more sophisticated tools for tissue analysis and diagnosis," the head of Roche's diagnostics division, Daniel O'Day, said in a statement.
Privately-held BioImagene, based in Sunnyvale, specializes in producing high-resolution pictures from microscope slides and also provides image archiving and retrieval products for pathologists.
Analysts at Helvea said the acquisition would complement and strengthen Roche's existing diagnostics portfolio, particularly at its subsidiary Ventana Medical Systems Inc.
Switzerland-based Roche said it expects to complete the purchase of BioImagene in the coming weeks.
"The increasing complexity of new tests and technologies creates tremendous need for more sophisticated tools for tissue analysis and diagnosis," the head of Roche's diagnostics division, Daniel O'Day, said in a statement.
Privately-held BioImagene, based in Sunnyvale, specializes in producing high-resolution pictures from microscope slides and also provides image archiving and retrieval products for pathologists.
Analysts at Helvea said the acquisition would complement and strengthen Roche's existing diagnostics portfolio, particularly at its subsidiary Ventana Medical Systems Inc.
Switzerland-based Roche said it expects to complete the purchase of BioImagene in the coming weeks.
- About Us
- |
- Terms of Use
- |
-
RSS
- |
- Privacy Policy
- |
- Contact Us
- |
- Shanghai Call Center: 962288
- |
- Tip-off hotline: 52920043
- 娌狪CP璇侊細娌狪CP澶05050403鍙-1
- |
- 浜掕仈缃戞柊闂讳俊鎭湇鍔¤鍙瘉锛31120180004
- |
- 缃戠粶瑙嗗惉璁稿彲璇侊細0909346
- |
- 骞挎挱鐢佃鑺傜洰鍒朵綔璁稿彲璇侊細娌瓧绗354鍙
- |
- 澧炲肩數淇′笟鍔$粡钀ヨ鍙瘉锛氭勃B2-20120012
Copyright 漏 1999- Shanghai Daily. All rights reserved.Preferably viewed with Internet Explorer 8 or newer browsers.